Patent ID: 11905333
Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of hematopoietic stem cell engraftment in a human subject, the method comprising:
(i) an ablative treatment to ablate endogenous hematopietic stem cells, comprising systemically administering to the subject a monoclonal antibody that specifically binds to human c-Kit at a dose effective to selectively ablate at least 20% of endogenous stem cells in the bone marrow of the subject, in the absence of radiation or chemotherapy;
(ii) a wash-out period of at least 7 days following administration of the monoclonal antibody that specifically binds to human c-Kit; and
(iii) transplantation of exogenous hematopoietic stem cells into the subject in a dose effective to achieve long term multilineage peripheral blood chimerism, wherein the transplantation is performed prior to 16 days following the administration of the monoclonal antibody that specifically binds to human c-Kit.